Danish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Side 1 fra 16 resultater
Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
FIELD OF THE INVENTION
The present invention relates generally to biology and medicine and more particularly to methods for treating obesity and obesity-related disorders.
BACKGROUND
Obesity is now a deadly global pandemic. The prevalence of overweight plus obesity among adults in USA in 2008 was
Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
The present invention relates to a novel combination therapy for diabetes mellitus type I and/or for obesity and its concomitant and/or secondary diseases or conditions, in particular the metabolic syndrome and/or syndrome X, and/or diabetes mellitus type II, by administering a combination of at
Kv1.3 potassium channel antagonists
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
CROSS-REFERENCE TO RELATED PATENT APPLICATIONS
This application is a U.S. National Phase Application under 35 U.S.C. .sctn. 371 of International Patent Application No. PCT/EP2015/060073, filed May 7, 2015, and claims priority to Great Britain Application No. 1408135.0, filed May 8, 2014, each of
Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
TECHNICAL FIELD
This invention relates to the fields of pharmaceutical and organic chemistry. Embodiments of the present invention relate to, and provide spiro azepane-oxazolidinones(1-oxa-3,8-diazaspiro-[4.6]undecan-2-ones) as voltage gated Kv1.3 potassium channel blockers, and intermediates,
Agent for preventing or ameliorating obesity
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
FIELD OF THE INVENTION
The present invention relates to an agent for preventing or ameliorating obesity, to an agent for inhibiting accumulation of visceral fat, to an agent for inhibiting accumulation of liver lipid, and to an agent for preventing or ameliorating fatty liver.
BACKGROUND OF THE
Dietary supplement and dietary methods employing said supplement for the treatment of obesity
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
BACKGROUND OF THE INVENTION
In the Specification of my copending Application Ser. No. 338,257 (U.S. Pat. No. 4,009,265), there is described and claimed a method for the treatment of obesity in man, which comprises the steps of giving the overweight patient a daily diet consisting essentially of,
(a)
Modulation of the sulfonylurea receptor and calcium in adipocytes for treatment of obesity/diabetes
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
FIELD OF THE INVENTION
This invention relates to methods of identification of the sulfonylurea receptor in human adipocytes and other adipocyte-selective calcium channels and calcium mobilization antagonists and use of these factors for treatment of obesity, diabetes, and insulin-resistance related
Dysfunctional satiety center syndrome and method of treatment therefor
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
TECHNICAL FIELD
The present invention relates generally to formulations for assisting in weight control in mammals, for example humans, and more particularly to such a formulation that is a composition containing measured proportions of a plurality of vitamins and minerals.
BACKGROUND OF THE
Combination therapeutic compositions
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
FIELD OF INVENTION
In general, the present invention relates to pharmaceutical compositions, and more particularly, to pharmaceutical compositions for the treatment of diabetes mellitus using combination therapy.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a term generally used to refer to
Combination therapeutic compositions and method of use
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
FIELD OF INVENTION
In general, the present invention relates to pharmaceutical compositions, and more particularly, to pharmaceutical compositions for the treatment of diabetes mellitus using combination therapy.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a term generally used to refer to
Combination therapeutic compositions and method of use
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
FIELD OF INVENTION
In general, the present invention relates to pharmaceutical compositions, and more particularly, to pharmaceutical compositions for the treatment of diabetes mellitus using combination therapy.
BACKGROUND OF THE INVENTION
Diabetes mellitus is a term generally used to refer to
Controlled- or delayed-release forms of topiramate
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. TOPIRAMATE
Topiramate is a
Topiramate salts and compositions comprising and methods of making and using the same
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. Topiramate
Topiramate is a
Topiramate sodium trihydrate
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
1. FIELD OF INVENTION
This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of seizures, epilepsy, tremors, affective disorders, obesity, neuropathic pain, and migraines.
2. BACKGROUND OF THE INVENTION
2.1. Topiramate
Topiramate is a
Slim and aqua concentrate having standardized and triple salt stabilized (-)-Hydroxycitric acid from Garcinia cambogia extract for making concentrate and slimming water and their derived product for weight management
Kun registrerede brugere kan oversætte artikler
Log ind / Tilmeld
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a slim and aqueous extract of Garcinia cambogia standardized to (-)-Hydroxycitric acid ((-)-HCA) as dietary product for weight management. The aqueous extract is further stabilized with triple salt of calcium, magnesium and potassium,
Den mest komplette database med medicinske urter understøttet af videnskab
- Arbejder på 55 sprog
- Urtekurer, der understøttes af videnskab
- Urtegenkendelse ved billede
- Interaktivt GPS-kort - tag urter på stedet (kommer snart)
- Læs videnskabelige publikationer relateret til din søgning
- Søg medicinske urter efter deres virkninger
- Organiser dine interesser og hold dig opdateret med nyhedsundersøgelser, kliniske forsøg og patenter
Skriv et symptom eller en sygdom, og læs om urter, der kan hjælpe, skriv en urt og se sygdomme og symptomer, den bruges mod.
* Al information er baseret på offentliggjort videnskabelig forskning
